Which of the following medications is representative of high-intensity statin therapy

Statins
Atorvastatin (Lipitor)
Fluvastatin (Lescol XL)
Lovastatin (Altoprev)
Pitavastatin (Livalo)
Pravastatin (Pravachol)
Rosuvastatin (Crestor)
Simvastatin (Zocor) Decrease LDL and triglycerides; slightly increase HDL Muscle pain, increased blood sugar levels, constipation, nausea, diarrhea, stomach pain, cramps, elevation of liver enzymes Cholesterol absorption inhibitor
Ezetimibe (Zetia) Decreases LDL; slightly decreases triglycerides; slightly increases HDL Stomach pain, diarrhea, fatigue, muscle soreness; avoid during pregnancy and lactation PCSK9 inhibitors
Alirocumab (Praluent)
Evolocumab (Repatha) Decrease LDL; usually reserved for people who have a genetic condition that causes very high LDL levels or people with heart disease who cannot tolerate statins or other cholesterol lowering drugs Itching, swelling, pain or bruising at injection site Citrate lyase inhibitors
Bempedoic acid (Nexletol)
Bempedoic acid-ezetimibe (Nexlizet) Decrease LDL Muscle spasms and joint pain, including acute gout Bile acid sequestrants
Cholestyramine (Prevalite)
Colesevelam (Welchol)
Colestipol (Colestid) Decrease LDL; may slightly increase HDL Constipation, bloating, nausea, gas, heartburn Combination cholesterol absorption inhibitor and statin
Ezetimibe-simvastatin (Vytorin) Decreases LDL and triglycerides; increases HDL Stomach pain, fatigue, gas, constipation, abdominal pain, cramps, muscle soreness, pain and weakness Combination calcium channel blocker and statin
Amlodipine-atorvastatin (Caduet) The statin component decreases LDL and triglycerides; the calcium channel blocker lowers blood pressure Facial and neck flushing, dizziness, heart palpitations, muscle soreness and pain, increased blood sugar levels, constipation, nausea, diarrhea, stomach pain, cramps, elevation of liver enzymes Fibrates
Fenofibrate (Antara, Lipofen, others)
Gemfibrozil (Lopid) Decrease triglycerides; modestly decrease LDL; increase HDL Nausea, stomach pain, muscle pain Niacin
Prescription niacin (Niacor, Niaspan) Decreases LDL and triglycerides; increases HDL Facial and neck flushing, itching, stomach upset, increase in blood sugar Omega-3 fatty acids
Prescription versions include Lovaza, Omacor and Vascepa Decrease triglycerides; may increase HDL Belching, fishy taste, indigestion; may increase risk of bleeding

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

1. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AFH, Stroes E, Taskinen MR, Tybjaerg-Hansen A, for the European Atherosclerosis Society Consensus Panel Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–3490. [PMC free article] [PubMed] [Google Scholar]

2. Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41:2313–30. 10.1093/eurheartj/ehz962. [PMC free article] [PubMed]

3. Besseling J, Hovingh GK, Huijgen R, Kastelein JJP, Hutten BA. Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. J Am Coll Cardiol. 2016;68:252–260. [PubMed] [Google Scholar]

4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J. 2020;41:111–188. [PubMed] [Google Scholar]

5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA 2018 Guideline on the management of blood cholesterol. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285–e350. [PubMed] [Google Scholar]

6. Brunham LR, Ruel I, Aljenedil S, Rivière JB, Baass A, Tu JV, Mancini GBJ, Raggi P, Gupta M, Couture P, Pearson GJ, Bergeron J, Francis GA, McCrindle BW, Morrison K, St-Pierre J, Henderson M, Hegele RA, Genest J, Goguen J, Gaudet D, Paré G, Romney J, Ransom T, Bernard S, Katz P, Joy TR, Bewick D, Brophy J. Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018. Can J Cardiol. 2018;34:1553–1563. [PubMed] [Google Scholar]

7. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol. 2015;9:129–169. [PubMed] [Google Scholar]

8. Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M, Dobashi K, Nohara A, Bujo H, Miyauchi K, Yamashita S, Yokote K, Working Group by Japan Atherosclerosis Society for Making Guidance of Familial Hypercholesterolemia Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25:751–770. [PMC free article] [PubMed] [Google Scholar]

9. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(s2):1–87. [PubMed] [Google Scholar]

10. Beheshti SO, Madsen CM, Varbo A. Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75:2553–2526. [PubMed] [Google Scholar]

11. Hu PW, Dharmayat KI, Stevens CAT, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation. 2020;141:1742–1759. [PubMed] [Google Scholar]

12. Sharifi M, Futema M, Nair D, Humphries SE. Genetic architecture of familial hypercholesterolaemia. Curr Cardiol Rep. 2017;19:44. [PMC free article] [PubMed] [Google Scholar]

13. Chan DC, Watts GF. Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box. Metabolism. 2012;61:3–11. [PubMed] [Google Scholar]

14. Ooi EMM, Barrett PHR, Watts GF. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies. Int J Cardiol. 2013;68:1811–1818. [PubMed] [Google Scholar]

15. Adorni MP, Zimetti F, Puntoni M. Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis. J Lipid Res. 2012;53:984–989. [PMC free article] [PubMed] [Google Scholar]

16. Versmissen J, Vongpromek R, Yahya R. Familial hypercholesterolaemia: cholesterol efflux and coronary disease. Eur J Clin Investig. 2016;46:643–650. [PMC free article] [PubMed] [Google Scholar]

17. Ogura M, Hori M, Harada-Shiba M. Association between cholesterol efflux capacity and atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2016;36:181–188. [PubMed] [Google Scholar]

18. Chan DC, Pang J, Hooper AJ, Burnett JR, Bell DA, Bates TR, van Bockxmeer FM, Watts GF. Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. Int J Cardiol. 2015;201:633–638. [PubMed] [Google Scholar]

19. Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, Padró T, Muñiz O, Díaz-Díaz JL, Mauri M, Ordovás JM, Mata P, SAFEHEART Investigators Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014;63:1982–1989. [PubMed] [Google Scholar]

20. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262–268. [PubMed] [Google Scholar]

21. Santos PC, Pereira AC. Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment. Pharmacogenomics. 2015;16:1743–1750. [PubMed] [Google Scholar]

22. Carmena R, Roederer G, Mailloux H, et al. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism. 1993;42:895–901. [PubMed] [Google Scholar]

23. Feng Q, Wei WQ, Chung CP, Levinson RT, Bastarache L, Denny JC, Stein CM. The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. Pharmacogenomics J. 2017;17:204–208. [PMC free article] [PubMed] [Google Scholar]

24. Postmus I, Trompet S, Deshmukh HA, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5:5068. [PMC free article] [PubMed] [Google Scholar]

25. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJP, Hutten BA. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27:1803–1810. [PubMed] [Google Scholar]

26. Mamann N, Lemale J, Karsenty A, Dubern B, Girardet JP, Tounian P. Intermediate-term efficacy and tolerance of statins in children. J Pediatr. 2019;210:161–165. [PubMed] [Google Scholar]

27. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst. 2019;11:CD006401. doi: 10.1002/14651858.CD006401.pub5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

28. Braamskamp MJ, Kusters DM, Avis HJ, et al. Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence. Paediatr Drugs. 2015;17:159–166. [PMC free article] [PubMed] [Google Scholar]

29. Kusters DM, Avis HJ, de Groot E, Wijburg FA, Kastelein JJP, Wiegman A, Hutten BA. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA. 2014;312:1055–1057. [PubMed] [Google Scholar]

30. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Steinhagen-Thiessen E, Stroes ES, Taskinen MR, Tybjærg-Hansen A, Wiklund O, European Atherosclerosis Society Consensus Panel Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36:2425–2437. [PMC free article] [PubMed] [Google Scholar]

31. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol. 2014;171:309–325. [PubMed] [Google Scholar]

32. Ramaswami U, Humphries SE, Priestley-Barnham L, et al. Current management of children and young people with heterozygous familial hypercholesterolaemia-HEART UK statement of care. Atherosclerosis. 2019;290:1–8. [PubMed] [Google Scholar]

33. Harada-Shiba M, Ohta T, Ohtake A, Ogura M, Dobashi K, Nohara A, Yamashita S, Yokote K, Joint Working Group by Japan Pediatric Society and Japan Atherosclerosis Society for Making Guidance of Pediatric Familial Hypercholesterolemia Guidance for pediatric familial hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25:539–553. [PMC free article] [PubMed] [Google Scholar]

34. Braamskamp MJ, Langslet G, McCrindle BW, et al. Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study. Circulation. 2017;136:359–366. [PubMed] [Google Scholar]

35. Braamskamp MJ, Langslet G, McCrindle BW, et al. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: results from the CHARON study. J Clin Lipidol. 2015;9:741–750. [PubMed] [Google Scholar]

36. Luirink I, Wiegman A, Kusters D, et al. 20-year follow-up of statins in children with familial hypercholesterolaemia. N Engl J Med. 2019;381:1547–1556. [PubMed] [Google Scholar]

37. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA, Sr, Flack JM. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631–2639. [PubMed] [Google Scholar]

38. Ference BA, Schunkert H, Watts GF, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–2472. [PMC free article] [PubMed] [Google Scholar]

39. Perez de Isla L, Alonso R, Watts GF, et al. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up. J Am Coll Cardiol. 2016;67:1278–1285. [PubMed] [Google Scholar]

40. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJP, Sijbrands EJG. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Br Med J. 2008;337:a2423. [PMC free article] [PubMed] [Google Scholar]

41. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE, on behalf of the Simon Broome Familial Hyperlipidaemia Register Group Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29:2625–2633. [PMC free article] [PubMed] [Google Scholar]

42. •• Nayak A, Hayen A, Zhu L, et al. Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis. BMJ Open. 2018:e020584 A meta-analysis that supports the post-trial statin legacy on cardiovascular disease and all-cause mortality. [PMC free article] [PubMed]

43. Pérez de Isla L, Arroyo-Olivares R, Muñiz-Grijalvo O, et al. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: the SAFEHEART study. J Clin Lipidol. 2019;13:989–996. [PubMed] [Google Scholar]

44. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, Marais AD. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124:2202–2207. [PubMed] [Google Scholar]

45. Humphries S, Cooper J, Seed M, Capps N, Durrington PN, Jones B, McDowell I, Soran H, Neil HAW, Simon Broome Familial Hyperlipidaemia Register Group Coronary heart disease mortality in treated familial hypercholesterolaemia: update of the UK Simon Broome FH register. Atherosclerosis. 2018;274:41–46. [PMC free article] [PubMed] [Google Scholar]

46. Bos S, Duvekot MHC, ten Kate G-JR, Verhoeven AJM, Mulder MT, Schinkel AFL, Nieman K, Watts GF, Sijbrands EJG, Roeters van Lennep JE. Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: a case control study. Atherosclerosis. 2017;256:62–66. [PubMed] [Google Scholar]

47. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577–581. [PubMed] [Google Scholar]

48. Moroi M, Nagayama D, Hara F, Saiki A, Shimizu K, Takahashi M, Sato N, Shiba T, Sugimoto H, Fujioka T, Chiba T, Nishizawa K, Usui S, Iwasaki Y, Tatsuno I, Sugi K, Yamasaki J, Yamamura S, Shirai K. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol. 2020;305:139–146. [PubMed] [Google Scholar]

49. Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland coronary prevention study) 5-year randomized trial and 20-year observational follow-up. Circulation. 2017;136:1878–1891. [PubMed] [Google Scholar]

50. Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, Retterstøl K. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis. 2006;189:451–457. [PubMed] [Google Scholar]

51. Eapen DJ, Valiani K, Reddy S, Sperling L. Management of familial hypercholesterolemia during pregnancy: case series and discussion. J Clin Lipidol. 2012;6:88–91. [PubMed] [Google Scholar]

52. Toleikyte I, Rettterstol K, Leren TP, et al. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation. 2011;124:1606–1614. [PubMed] [Google Scholar]

53. Wierzbicki AS, Humphries SE, Minhas R. Guideline Development Group. Familial hypercholesterolaemia: summary of NICE guidelines. BMJ. 2008;337:a1095. [PubMed] [Google Scholar]

54. Botha TC, Pilcher GJ, Wolmarans K, et al. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: a retrospective review of 39 pregnancies. Atherosclerosis. 2018;277:502–507. [PubMed] [Google Scholar]

55. Cholesterol Treatment Trialists’ Collaboration Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407–415. [PMC free article] [PubMed] [Google Scholar]

56. Ward NC, Watts GF, Eckel RH. Statin toxicity: mechanistic insights and clinical implications. Circ Res. 2019;124:328–350. [PubMed] [Google Scholar]

57. de Goma EM, Ahmad ZS, O’Brien EC, et al. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: Data from the CASCADE-FH Registry. Circ Cardiovasc Genet. 2016;9:240–249. [PMC free article] [PubMed] [Google Scholar]

58. Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, Banach M. Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs. 2018;18:157–173. [PMC free article] [PubMed] [Google Scholar]

59. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78:684–698. [PMC free article] [PubMed] [Google Scholar]

60. Rodriguez F, Maron DJ, Knowles JW, et al. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4:206–213. [PMC free article] [PubMed] [Google Scholar]

61. Galema-Boers JM, Lenzen MJ, van Domburg RT, et al. Predicting non-adherence in patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 2014;70:391–397. [PubMed] [Google Scholar]

62. Hagger MS, Hardcastle SJ, Hu M, Kwok S, Lin J, Nawawi HM, Pang J, Santos RD, Soran H, Su TC, Tomlinson B, Watts GF. Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia. Atherosclerosis. 2018;277:493–501. [PubMed] [Google Scholar]

63. Matthews A, Herrett E, Gasparrini A, et al. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ. 2016;353. [PMC free article] [PubMed]

64. Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016;37:908–916. [PubMed] [Google Scholar]

65. •• Watts GF, Gidding SS, Mata P et al. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol. 2020;17:360-377. A comprehensive review on the contemporary management of FH. [PubMed]

66. Pang J, Sullivan DR, Brett T, Kostner KM, Hare DL, Watts GF. Familial hypercholesterolaemia in 2020: a leading tier 1 genomic application. Heart Lung Circ. 2020;29:619–633. [PubMed] [Google Scholar]

67. Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb. 2017;24:19–25. [PMC free article] [PubMed] [Google Scholar]

68. Hu M, Lui SS, Ko GT, et al. Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies. Int J Cardiol. 2013;168:3071–3073. [PubMed] [Google Scholar]

69. Yang J, Li LJ, Wang K, He YC, Sheng YC, Xu L, Huang XH, Guo F, Zheng QS. Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients. Acta Pharmacol Sin. 2011;32:116–125. [PMC free article] [PubMed] [Google Scholar]

70. Tomlinson B, Chan P, Liu ZM. Statin responses in Chinese patients. J Atheroscler Thromb. 2018;25:199–202. [PMC free article] [PubMed] [Google Scholar]

71. Harada-Shiba M, Kastelein JJP, Hovingh GK, Ray KK, Ohtake A, Arisaka O, Ohta T, Okada T, Suganami H, Wiegman A. Efficacy and safety of pitavastatin in children and adolescents with familial hypercholesterolemia in Japan and Europe. J Atheroscler Thromb. 2018;25:422–429. [PMC free article] [PubMed] [Google Scholar]

72. Vuorio A, Watts GF, Schneider WJ, et al. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. J Intern Med. 2020;287:2–18. [PubMed] [Google Scholar]

73. •• Tsimikas S, Gordts PLSM, Nora C, et al. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41:2275–84. 10.1093/eurheartj/ehz310A large meta-analysis on the effect of statin therapy on Lp(a) levels.

74. Yahya R, Berk K, Verhoeven A, Bos S, van der Zee L, Touw J, Erhart G, Kronenberg F, Timman R, Sijbrands E, Roeters van Lennep J, Mulder M. Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype. Atherosclerosis. 2019;289:201–205. [PubMed] [Google Scholar]

75. Trinder M, DeCastro ML, Azizi H, et al. Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia. J Am Coll Cardiol. 2020;75:2682–2693. doi: 10.1016/j.jacc.2020.03.065. [PubMed] [CrossRef] [Google Scholar]

76. Neefjes LA, Ten Kate GJ, Alexia R, et al. Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. 2011;219:721–727. [PubMed] [Google Scholar]

77. Miname MH, Ribeiro MS, Parga Filho J, et al. Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. Atherosclerosis. 2010;213:486–491. [PubMed] [Google Scholar]

78. Miname MH, Bittencourt MS, Moraes SR, et al. Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy. JACC Cardiovasc Imaging. 2019;12:1797–1804. [PubMed] [Google Scholar]

79. Puri R, Nicholls SJ, Shao M, Kataoka Y, Uno K, Kapadia SR, Tuzcu EM, Nissen SE. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65:1273–1282. [PubMed] [Google Scholar]

80. Henein M, Granasen G, Wiklund U, et al. High dose and long-term statin therapy accelerate coronary artery calcification. Int J Cardiol. 2015;184:581–586. [PubMed] [Google Scholar]

81. Lee SE, Sung JM, Andreini D, Budoff MJ, Cademartiri F, Chinnaiyan K, Choi JH, Chun EJ, Conte E, Gottlieb I, Hadamitzky M, Kim YJ, Kumar A, Lee BK, Leipsic JA, Maffei E, Marques H, Pontone G, Raff G, Shin S, Stone PH, Samady H, Virmani R, Narula J, Berman DS, Shaw LJ, Bax JJ, Lin FY, Min JK, Chang HJ. Differential association between the progression of coronary artery calcium score and coronary plaque volume progression according to statins: the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging (PARADIGM) study. Eur Heart J Cardiovasc Imaging. 2019;20:1307–1314. [PMC free article] [PubMed] [Google Scholar]

82. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, ESC Scientific Document Group. Neumann FJ, Sechtem U, Banning AP, Bonaros N, Bueno H, Bugiardini R, Chieffo A, Crea F, Czerny M, Delgado V, Dendale P, Flachskampf FA, Gohlke H, Grove EL, James S, Katritsis D, Landmesser U, Lettino M, Matter CM, Nathoe H, Niessner A, Patrono C, Petronio AS, Pettersen SE, Piccolo R, Piepoli MF, Popescu BA, Räber L, Richter DJ, Roffi M, Roithinger FX, Shlyakhto E, Sibbing D, Silber S, Simpson IA, Sousa-Uva M, Vardas P, Witkowski A, Zamorano JL, Achenbach S, Agewall S, Barbato E, Bax JJ, Capodanno D, Cuisset T, Deaton C, Dickstein K, Edvardsen T, Escaned J, Funck-Brentano C, Gersh BJ, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Prescott E, Saraste A, Storey RF, Svitil P, Valgimigli M, Windecker S, Aboyans V, Baigent C, Collet JP, Dean V, Delgado V, Fitzsimons D, Gale CP, Grobbee D, Halvorsen S, Hindricks G, Iung B, Jüni P, Katus HA, Landmesser U, Leclercq C, Lettino M, Lewis BS, Merkely B, Mueller C, Petersen S, Petronio AS, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Touyz RM, Benkhedda S, Metzler B, Sujayeva V, Cosyns B, Kusljugic Z, Velchev V, Panayi G, Kala P, Haahr-Pedersen SA, Kabil H, Ainla T, Kaukonen T, Cayla G, Pagava Z, Woehrle J, Kanakakis J, Tóth K, Gudnason T, Peace A, Aronson D, Riccio C, Elezi S, Mirrakhimov E, Hansone S, Sarkis A, Babarskiene R, Beissel J, Maempel AJC, Revenco V, de Grooth GJ, Pejkov H, Juliebø V, Lipiec P, Santos J, Chioncel O, Duplyakov D, Bertelli L, Dikic AD, Studenčan M, Bunc M, Alfonso F, Bäck M, Zellweger M, Addad F, Yildirir A, Sirenko Y, Clapp B. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC) Eur Heart J. 2020;41:407–477. [PubMed] [Google Scholar]

83. Castiglione V, Chiriacò M, Emdin M, et al. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020;6:258–9. 10.1093/ehjcvp/pvaa042. [PMC free article] [PubMed]

84. Babelova A, Sedding DG, Brandes RP. Anti-atherosclerotic mechanisms of statin therapy. Curr Opin Pharmacol. 2013;13:260–264. [PubMed] [Google Scholar]

86. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, Brown TS, der Nigoghossian C, Zidar DA, Haythe J, Brodie D, Beckman JA, Kirtane AJ, Stone GW, Krumholz HM, Parikh SA. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75:2352–2371. [PMC free article] [PubMed] [Google Scholar]

87. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. [PMC free article] [PubMed] [Google Scholar]

88. Vuorio A, Watts GF, Kovanen PT. Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk. J Intern Med. 2020;287:746–747. [PubMed] [Google Scholar]

91. Barton Duell P, Gidding SS, Andersen RL, et al. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: the CASCADE FH registry. Atherosclerosis. 2019;289:85–93. [PubMed] [Google Scholar]

92. Defesche JC, Stefanutti C, Langslet G, et al. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017;11:1338–1346. [PubMed] [Google Scholar]

93. Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: guidelines and new therapies. Atherosclerosis. 2018;277:483–492. [PubMed] [Google Scholar]

94. Lázaro P, Pérez de Isla L, Watts GF, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol. 2017;11:260–271. [PubMed] [Google Scholar]

95. • Ademi Z, Norman R, Pang J, et al. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment? Atherosclerosis. 2020;304:1–8. 10.1016/j.atherosclerosis.2020.05.007This study supports the cost-effectiveness for screening and treating children with FH. [PubMed]

96. Klančar G, Grošelj U, Kovač J, Bratanič N, Bratina N, Trebušak Podkrajšek K, Battelino T. Universal screening for familial hypercholesterolemia in children. J Am Coll Cardiol. 2015;66:1250–1257. [PubMed] [Google Scholar]

97. Wald DS, Bestwick JP, Morris JK, Whyte K, Jenkins L, Wald NJ. Child–parent familial hypercholesterolemia screening in primary care. N Engl J Med. 2016;375:1628–1637. [PubMed] [Google Scholar]

98. Athyros VG, Boutari C, Imprialos K, et al. Inclisiran. A new kid on the new block for treating hypercholesterolaemia. Curr Vasc Pharmacol. 2020. 10.2174/1570161118999200428225849. [PubMed]

99. Hibbitt O, Agkatsev S, Owen C, et al. RNAi-mediated knockdown of HMG CoA reductase enhances gene expression from physiologically regulated low-density lipoprotein receptor therapeutic vectors in vivo. Gene Ther. 2012;9:463–467. [PubMed] [Google Scholar]

100. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O’Dea L, Witztum JL, AKCEA-APO(a)-LRx Study Investigators Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244–255. [PubMed] [Google Scholar]

Which are the high intensity statins?

Is rosuvastatin a high intensity statin?

Is lovastatin a high intensity statin?

When is high intensity statin indicated?